BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28969912)

  • 21. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
    Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
    Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [MicroRNA expression signature profile and its clinical significance in endometrioid carcinoma].
    Wang Y; Adila S; Zhang X; Dong Y; Li W; Zhou M; Li T
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):88-94. PubMed ID: 24742567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis.
    Huang TT; Ping YH; Wang AM; Ke CC; Fang WL; Huang KH; Lee HC; Chi CW; Yeh TS
    Oncotarget; 2015 Jul; 6(20):18012-26. PubMed ID: 26041881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs).
    Catanzaro G; Sabato C; Russo M; Rosa A; Abballe L; Besharat ZM; Po A; Miele E; Bellavia D; Chiacchiarini M; Gessi M; Peruzzi G; Napolitano M; Antonelli M; Mastronuzzi A; Giangaspero F; Locatelli F; Screpanti I; Vacca A; Ferretti E
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
    Devor EJ; Schickling BM; Reyes HD; Warrier A; Lindsay B; Goodheart MJ; Santillan DA; Leslie KK
    Oncol Rep; 2016 Apr; 35(4):2461-5. PubMed ID: 26847831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer.
    Wilczynski M; Danielska J; Domanska-Senderowska D; Dzieniecka M; Szymanska B; Malinowski A
    Acta Obstet Gynecol Scand; 2018 May; 97(5):560-569. PubMed ID: 29355888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expression of the miRNA-200 family in endometrial endometrioid carcinoma.
    Lee JW; Park YA; Choi JJ; Lee YY; Kim CJ; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
    Gynecol Oncol; 2011 Jan; 120(1):56-62. PubMed ID: 21035172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
    Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
    Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
    Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
    Yoneyama K; Ishibashi O; Kawase R; Kurose K; Takeshita T
    Anticancer Res; 2015 Mar; 35(3):1401-10. PubMed ID: 25750291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
    Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson Jackson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
    Gynecol Oncol; 2023 Oct; 177():38-45. PubMed ID: 37634258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer.
    Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A; Gilabert-Estellés J
    Hum Reprod; 2012 Oct; 27(10):3036-45. PubMed ID: 22904162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of microRNA in tumor cells of endmetrioid carcinoma of endometrium.
    Buchynska LG; Borykun TV; Iurchenko NP; Nespryadko SV; Nesina IP
    Exp Oncol; 2020 Dec; 42(4):289-294. PubMed ID: 33355860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
    Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
    Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
    Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
    Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
    Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
    FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.